Robert Scannevin, PhD
Chief Scientific Officer, Verge Genomics
Dr. Scannevin has more than 21 years of leadership experience in drug discovery and development at both large pharma and early-stage biotech, and has seen multiple drugs from discovery through FDA approval. Before joining Verge, Dr. Scannevin was the Head of Research at Yumanity Therapeutics, where he built a drug discovery function that delivered robust preclinical and clinical pipelines. Dr. Scannevin provided scientific leadership through multiple successful private financing rounds, a collaboration with a major large pharmaceutical company, and a successful public debut. Prior to Yumanity, Dr. Scannevin held leadership roles at Biogen, Johnson and Johnson and Wyeth. While at Biogen, Dr. Scannevin was heavily involved in the development and marketing approval of Tecfidera® (dimethyl fumarate), an oral therapeutic for multiple sclerosis, in which he served as the Global Research Lead for this first-in-class therapy. Dr. Scannevin earned his Ph.D. at SUNY Stony Brook and received his postdoctoral training at the Johns Hopkins University School of Medicine. He is a co-author on more than 55 peer-reviewed research articles and an inventor on over a dozen patent applications and issued patents.